Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?

Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’

In Brief for June 22, 2022

Journal of Thoracic Oncology Impact Factor Surpasses 20

Step It Up For Research!

Foundation Announces 2022 Young Investigator Grant Recipients

Workshops Offer Opportunities for Education, Networking Based on Shared Interests, Specialties

WCLC Chairs Welcome Opportunity to Gather Face-to-Face